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PMS1 RISK ASSESSMENT OF CARDIOVASCULAR THROMBOTIC EVENTS, OTHER CARDIAC EVENTS, AND MORTALITY AMONG VETERANS AFFAIRS PATIENTS WITH DIFFICULT TO MANAGE GOUT
Raisch DW 1 , Rice J 2 , Campbell HM 2 1 University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2 Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA OBJECTIVES: Gout patients in the Department of Veterans Affairs (VA) are often difficult to manage (DTM) with multiple co-morbidities (diabetes, hypertension, renal disease) that are associated with cardiovascular thrombotic events (CVTE) and other cardiac events (OCE). Our objectives were to describe rates of CVTE and OCE among patients with gout and to determine if increased CVTE or OCE occurred in patients with DTM gout. METHODS: We used VA national databases to select all patients with gout diagnoses (ICD-9 274.xx) in an index year of 2004 with follow-up through 2006. We identified patients with ICD-9 codes for OCEs and CVTE diagnoses, based upon definitions from the Antiplatelet Trialists' Collaboration. ICD-9 codes for gout nephropathy or tophi were used to identify DTM patients. We calculated odds ratios with 95% confidence intervals (OR, CI) The total number of 16,311 individual case reports of leflunomide adverse events were registered in the Vigibase, compared to 32,945 and 5,011 for methotrexate and sulfasalazine, respectively. There were 108 death cases registered for leflunomide, 236 for methotrexate and 18 for sulfasalazine. Most frequent system-organ classes reported were: gastro-intestinal system disorders (13.2%) and skin and appendages disorders (9,8%) for leflunomide, respiratory system disorders (11.6%) and general disorders (10.8%) for methotrexate and skin and appendages disorders (17.7%) and general disorders (14.6%) for sulfasalazine. 
PMS3 PROPORTION OF PATIENTS WITH OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PERFORMING A BONE MINERAL DENSITY DIAGNOSIS MEASUREMENT: THE PRESAGE STUDY
Guggenbuhl P 1 , Dufour R 2 , Liu-Leage S 3 , Tcherny S 3 , Sapin H 3 , Cortet B 4 1 CHU Rennes, Rennes, France, 2 Institut sainte catherine, Avignon, France, 3 Lilly France, Suresnes, France, 4 CHRU Lille, Lille, France OBJECTIVES: The primary objective was to estimate the proportion of patients suffering from osteoporosis among postmenopausal women who could benefit from therapeutic recommendations according to the French guidelines after performing a BMD diagnosis measurement. METHODS: Cross sectional observational study was performed of postmenopausal women, not treated for osteoporosis for at least one year and who could benefit from therapeutic recommendations according to the French guidelines after performing a BMD. RESULTS: A total of 647 postmenopausal women were enrolled (646 analyzed) by 78 rheumatologists performing BMD measurement between May 2007 and January 2008. The BMD measurement were prescribed by rheumatologists (42.6%), GPs (34.1%), Ob/Gynecologist (18.1%) or other physicians (5.1%). The mean age was 66 9 years. According to the WHO definition, densitometry osteoporosis diagnosis was made in 57.6% patients (IC95% 53.7; 61.4), osteopenia diagnosis in 38.7% patients (IC95% 34.9; 42.6); and a normal BMD was established in 3.7% patients. A total of 39.7% of patients had at least a prevalent fracture and a treatment other than calcium and vitamin D supplementation was recommended in 93.0% cases of osteoporosis, in 44.8% in case of osteopenia and 8.3% in case of normal BMD. In a logistic regression model, the factors influencing therapeutic decision making in this population were the osteoporosis diagnosis versus osteopenia diagnosis OR 21.0 (IC95% 12.5; 35.3), past or current glucocorticoids use OR 2.7 (IC95% 1.3; 5.7). The fracture type was also important in decision making; existing vertebral fracture versus none OR 17.2 (IC95% 5.8; 51.4), existing non vertebral fracture versus none OR 4.7 (IC95% 2.7; 8.4). CONCLUSIONS: In a real setting, osteoporosis was diagnosed in approximately 60% of the women who underwent a BMD diagnosis and who complied with the French therapeutic guidelines. Therapeutic recommendations decision making was influenced mainly by BMD results, followed by prevalent fracture and fracture types and glucocorticoids use. To evaluate the efficacy and safety of the centrally acting analgesic, tapentadol ER, for the management of moderate to severe osteoarthritis knee pain; health status was evaluated using the EuroQol-5 Dimension (EQ-5D) questionnaire.
